NewAmsterdam Pharma Q3 EPS $（0.61）错过$（0.41）预估，销售额$348.000K错过$528.7M预估

NewAmsterdam Pharma (NASDAQ: NAMS) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.41) by 47.34 percent. This is a 238.89 percent decrease over losses of $(0.18) per share from the same period last year. The company reported quarterly sales of $348.000 thousand which missed the analyst consensus estimate of $5.287 million by 93.42 percent. This is a 98.80 percent decrease over sales of $29.111 million the same period last year.